Padma Kodukula

Chief Business Officer, A-Alpha Bio

Padma Kodukula is a scientist with 25 years of life sciences experience, building technology platforms and successfully launching commercial products in the research, diagnostics, and pharma industries. Operating at the intersection of science and business, Padma has demonstrated expertise in building exponential company value by working on over 15 technology platforms spanning instruments, services, and reagents in genomics, proteomics, and data science in multiple therapeutic areas. Through strategic sales, out-license and partnership deals she has realized over $15B in aggregate revenue. Her core competencies and proven skills reside in corporate strategy, business development, fundraising (venture capital & non-dilutive), project & alliance management, drug development process, technology platform development, and commercial launches.

Currently serving as the Chief Business Officer of A-Alpha Bio, Padma is responsible for strategy, business development, supporting technology innovation, market development, and pharma partnerships. Before joining A-Alpha Bio, Kodukula led strategy and business development at Precision NanoSystems (acquired by Danaher Corporation in June 2021), where she successfully closed numerous business partnerships, driving value, and delivering on the company’s vision and growth objective. Prior to her work at Precision NanoSystems, Kodukula spent over a decade working within business development functions at Human Longevity, Inc., Life Technologies, and Prometheus Laboratories helping develop and foster collaborative partnerships with pharma, academia, and health systems.

As a previous board member and current strategic advisor, Padma is passionate about working with early-stage platform technology companies and management teams to innovate and launch disruptive products that impact the world. With a PhD in immunology from the University of Illinois, Chicago, and an MBA from San Diego State University, Kodukula combines both the scientific knowledge and business acumen to foster and accelerate the growth of transformative biotechnology companies.